Previous 10 | Next 10 |
WARREN, N.J., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the manageme...
Image source: The Motley Fool. Aquestive Therapeutics, Inc. (NASDAQ: AQST) Q3 2021 Earnings Call Nov 03, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Aquestive Therapeutics, Inc. (AQST) Q3 2021 Earnings Call Tran...
Aquestive Therapeutics, Inc. (AQST) Q3 2021 Earnings Conference Call November 3, 2021 08:00 AM ET Company Participants Bennett Watson - IR Keith Kendall - President & CEO Ernie Toth - CFO Dan Barber - COO Conference Call Participants Evan Hua - BMO Capital Markets Jason Butler - JMP Secur...
Aquestive Therapeutics (NASDAQ:AQST): Q3 GAAP EPS of -$0.37 beats by $0.06. Revenue of $13.28M (+60.0% Y/Y) beats by $2.27M. Press Release For further details see: Aquestive Therapeutics EPS beats by $0.06, beats on revenue
Libervant™ (diazepam) Buccal Film continues to progress through the FDA review process in advance of PDUFA goal date of December 23, 2021 AQST-109 top line Phase 1 trial demonstrates clinical results comparable to autoinjectors (such as EpiPen® and Auvi-Q®) for the em...
ADC, AFG, DADA, AIZ, AKAM, AMCR, AMED, AMGN, ANDE, APPS, AQST, ATVI, AWK, AYX, BFAM, BGFV, BKH, BTG, BXC, CASA, CDK, CDLX, CERS, CGBD, CHCT, CHK, CLW, COUR, CRK, [CSLT]], CVGI, CZR, DCP, DCPH, DENN, DHT, DOX, DRRX, [DVN]], EARN, EGHT, EIX, EKSO, ELVT, ENLC, EXAS, EXEL, FMC, FNF, FRG, GAIN, GN...
First and only orally delivered epinephrine product candidate AQST-109 demonstrates clinical results comparable to autoinjectors (such as EpiPen® and Auvi-Q®) for the emergency treatment of allergic reactions Median time to peak concentration (T max ) of ...
WARREN, N.J., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it will repo...
WARREN, N.J., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it has reach...
SAINT LAURENT, Quebec, Sept. 29, 2021 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSXV:IGX) (OTCQB:IGXT) (“IntelGenx”) today announced that its co-development and commercialization partner for Tadalafil oral films for the treatment of erectile dysfunction (“ED”) and ben...
News, Short Squeeze, Breakout and More Instantly...
Aquestive Therapeutics Inc. Company Name:
AQST Stock Symbol:
NASDAQ Market:
Aquestive Therapeutics Inc. Website:
Meets primary study endpoints with pharmacokinetics (PK) comparable whether Anaphylm is administered by subjects or by healthcare providers (HCPs) Final supportive study, the Oral Allergy Syndrome (OAS) challenge study, currently enrolling Continues to anticipate requesting a pr...
WARREN, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolog...
WARREN, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolog...